GSK Plc
Research GSK Plc (GSK) on Bullrun: valuation model: 43.6% undervalued, market cap USD 94.06B, P/E 14.6, dividend yield 3.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGSK
- ExchangeNYSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal43.6% undervalued
- Market capUSD 94.06B
- P/E14.6
- Dividend yield3.9%
- Financial periodQ2 2026
- RevenueGBP 8.41B
- Net incomeGBP 435.00M
- Free cash flowGBP 2.04B
- Gross margin73.1%
Valuation Snapshot
Bullrun's latest valuation model marks GSK Plc as 43.6% undervalued; latest market cap is USD 94.06B; P/E is 14.6; dividend yield is 3.9%.
Peer valuation comparison
Latest P/E is 14.65x versus a Healthcare sector median of 24.61x (40.5% below).
Latest dividend yield is 3.87% versus a Healthcare sector median of 1.84% (110.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 32.67B | GBP 5.72B | GBP 4.76B | 72.4% | 2.78 | GBP 3.15B | GBP 17.72B | GBP 16.38B |
| FY2024 | GBP 31.38B | GBP 2.58B | GBP 3.57B | 71.2% | 1.24 | GBP 3.69B | GBP 16.99B | GBP 13.67B |
| FY2023 | GBP 30.33B | GBP 4.93B | GBP 4.42B | 71.8% | 2.4 | GBP 2.75B | GBP 18.02B | GBP 13.35B |
| FY2022 | GBP 29.32B | GBP 14.96B | GBP 5.15B | 67.4% | 7.32 | GBP 3.52B | GBP 20.99B | GBP 10.60B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 94.06B | 14.6 | 3.9% | 1.82 |
| 2025 | 2025-12-31 | USD 98.39B | 13.4 | 3.4% | 1.68 |
| 2024 | 2024-12-31 | USD 69.01B | 21.4 | 4.6% | 1.57 |
| 2023 | 2023-12-29 | USD 75.53B | 10.2 | 3.8% | 1.39 |
| 2022 | 2022-12-30 | USD 71.94B | 4.1 | 4.8% | 1.68 |
| 2021 | 2021-12-31 | USD 88.76B | 14.1 | 5.0% | 2.21 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.82 USD, yield 3.9%.
| Year | Dividends/share |
|---|---|
| FY2025 | 1.68 GBP |
| FY2024 | 1.57 GBP |
| FY2023 | 1.39 GBP |
| FY2022 | 1.68 GBP |
About GSK Plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
ETFs that hold GSK Plc
GSK Plc is one of the ten largest holdings of 50 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| iShares Core FTSE 100 UCITS ETF (GBP Dist) | 3.14% | 0.07% |
| Vanguard FTSE 100 UCITS ETF | 3.17% | 0.09% |
| iSh Cor FTSE 100 GBP A | 2.96% | 0.07% |
| Vanguard FTSE 100 UCITS ETF GBP Accumulation | 3.17% | 0.09% |
| HSBC FTSE 100 UCITS ETF | 2.95% | 0.07% |
| iShares Edge MSCI Europe Value Factor UCITS ETF EUR (Acc) | 3.08% | 0.25% |
| iShares UK Dividend UCITS ETF GBP (Dist) | 3.17% | 0.40% |
| UBS MSCI United Kingdom UCITS ETF GBP acc | 3.24% | 0.20% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is GSK Plc overvalued or undervalued?
Bullrun's valuation model currently marks GSK Plc as 43.6% undervalued.
What is GSK Plc's market cap?
GSK Plc's market capitalization is USD 94.06B.
What is GSK Plc's P/E ratio?
GSK Plc's price-to-earnings (P/E) ratio is 14.6.
Does GSK Plc pay a dividend?
GSK Plc has a dividend yield of 3.9%.
What does GSK Plc do?
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.